<DOC>
	<DOCNO>NCT00199901</DOCNO>
	<brief_summary>The purpose trial ass whether treatment NY-ESO-1 ISCOMATRIX® vaccine improve outcomes people Malignant Melanoma remove , high risk relapse .</brief_summary>
	<brief_title>Study NY-ESO-1 ISCOMATRIX® Patients With High-risk , Resected Melanoma</brief_title>
	<detailed_description>NY-ESO-1 protein immune target find many cancer include melanoma . ISCOMATRIX® adjuvant enhances immune response . This trial compare NY-ESO-1 ISCOMATRIX® vaccine ISCOMATRIX® adjuvant alone assess whether treatment NY-ESO-1 ISCOMATRIX® vaccine improve outcome participant Malignant Melanoma remove , high risk recurrence . Eligible participant randomly allocate treatment arm . Treatment involve four intramuscular ( muscle ) injection ( 1 injection every 4 week x 3 , plus 1 injection 6 month ) . Participants assess recurrence melanoma , safety immune response ( blood test ) 18 month study period . Off study , doctor follow melanoma recurrence survival .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Histologically proven malignant melanoma . Tumor expression NYESO1 antigen immunohistochemistry . Fully resect AJCC stage IIc , IIIb , IIIc IV melanoma . Within six month surgery melanoma . Full recovery surgery . No immunotherapy systemic adjuvant therapy melanoma since recent relapse and/or resection . ( Previous adjuvant therapy accept provide pt relapse resect . ) Age 18 year old . Able give write informed consent . Vital laboratory parameter within normal range , protocol specify range . Other serious significant illness . Resected cerebral metastasis . Ocular melanoma . Other malignancy within last 3 year , except treat nonmelanoma skin cancer cervical cancer situ . Using immunosuppressive drug . Anticoagulation . Known HIV positivity . Chemotherapy radiation therapy last four week ( 6 week nitrosourea drug ) . Not available immunological clinical followup assessment . Participation prior clinical trial involve investigational agent within last 4 week . Previous isolated limb perfusion ( ILP ) . Pregnancy breastfeed . Refusal inability use effective mean contraception woman childbearing potential . Mental impairment may compromise ability give informed consent comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Phase II</keyword>
	<keyword>Randomized Controlled Trial</keyword>
	<keyword>Double-Blind</keyword>
	<keyword>Cancer Vaccine</keyword>
	<keyword>NY-ESO-1 protein , human</keyword>
	<keyword>ISCOMATRIX , immunological adjuvant</keyword>
</DOC>